drugset
drugset / Trial / NCT05315180

A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

NCT05315180 ↗

Phase 1 Unknown 80 enrolled Betta Pharmaceuticals Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.

Timeline

Start
2021-08-24
Primary completion
2023-07-31
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BPI-421286 Unknown — Oral

Indications

metastatic malignant neoplasm